CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Full Professor of the Department of Cell Biology and Development, Institute of Biomedical Sciences (ICB), University of São Paulo (USP), graduated in Medicine from the Faculty of Medicine of Ribeirão Preto - University of São Paulo (1980) and obtained the degrees of Master (1991) and Doctorate (1994) in Medicine (Clinical Endocrinology) at the Paulista School of Medicine - Unifesp and Associate Professor (2005) at ICB-USP. She is member of the Latin American Thyroid Society (LATS), the American Thyroid Association (ATA), the American Association for Cancer Research (AACR), the Brazilian Cellular Biology Society (SBBC) and the Brazilian Society of Endocrinology and Metabology (SBEM). She served as members of board of directors of LATS and SBEM-Thyroid, and as chair of SBEM-Thyroid Department (2009-2010). She was editor-in-chief (2007 -2010) of the Archives of Endocrinology Metabolism (AEM) - formely Arquivos Brasileiros de Endocrinologia e Metabologia (ABEM). Currently she contributes to the the editorial board of THYROID (EUA), AEM (Brazil), Brazilian J Med Biol Research (Brazil). The field of her research covers the understanding of Thyroid and Goiter Cancer tumorigenesis, with emphasis on the signaling pathways MAPK (BRAF), TGFbeta, iodine and microRNA using in vitro and in vivo models that include techniques of molecular biology, histology, cell biology, genomics, gene editing and animal model. She has been mentored undergraduate, graduate students and pos-doctoral fellows, and some of them presently are scientists in Brazil and abroad. For her contribution to the thyroid research she was awarded with the LATS Prize by the Latin American Thyroid Society in 2009 and the EBT-2016 Prize by the Department of Thyroid - SBEM. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Recently, the identification and clinical trials of new drugs that modulate oncogenic signaling, such as genetic alteration in the MAPK pathways that is involved in more than 70% of thyroid cancer cases, have been promoted a great advance in cancer treatment. Nevertheless, it is not rare that some tumors display resistance to these drugs due to activation of alternative signaling pathways…
Global incidence of thyroid cancer has increased in the last years, stating this type of cancer as the most common of the endocrine system. Although having a good prognosis, a fraction of thyroid cancers becomes refractory to conventional therapy of radioiodine ablation after thyroid tumor resection due to a more aggressive behavior. Despite the well characterized role for MAPK signaling …
Papillary thyroid cancer (PTC) is the most common histotype of thyroid cancer whose incidence has been rising progressively in the last decade. The most prevalent genetic alteration in PTC is BRAF mutation (BRAFT1799A), detected in more than 45% of patients. This mutation activates constitutively MAPK pathway, and moreover, amplify other signaling pathways involved in cell proliferation, …
(Only some records are available in English at this moment)
The CRISPR/Cas9 methodology has emerged as a promising tool for the precise modification of DNA sequences throughout the genome. Recently, the Casgevy, an CRISPR/Cas gene editing therapy in patients with sickle cell anemia and thalassemia, was approved in the United Kingdom. In the oncological context, CRISPR/Cas9 has been applied in the experimental study of cancers including thyroid c…
Chemoresistance is a major problem faced by oncologist in Cancer treatment. As our understanding of the molecular biology of Cancer has advanced, the concept of plasticity in Cancer has emerged as a key player in drug resistance. One of the major mechanisms responsible for tumor cell plasticity is the Epithelial-Mesenchimal Transition (EMT), which allows cell phenotype transition leading …
MicroRNAs (miRNAs) are small non-coding endogenous RNAs (~22 nucleotides) that have a potent action in the post-transcriptional regulation of gene expression, repressing translation by pairing in the 3' untranslated region (3'UTR) of the messenger RNA (mRNA) target. MicroRNAs are involved in the control of several biological processes related to tumorigenesis, such as cell differentiation…
(Only some records are available in English at this moment)
Thyroid cancer is the most frequent endocrine neoplasia and fifth most incident cancer in women. Papillary thyroid cancer (PTC) comprises 90% of thyroid cancer cases and presents good prognosis and curative treatment options. However, undifferentiated PTC and anaplastic thyroid cancer (ATC) are marked by loss of differentiation, i.e. loss of thyroid markers such as NIS, TPO, Tg and TSHR. …
miRNA deregulation is an important step in oncogenesis associated with activation of oncogenic pathway and inhibition of tumor-suppressor genes. During tumor progression, a complex network of miRNAs and its targets are modulated which is likely to contribute to metastatic phenotype and tumor spreading. Metastases are the main cause of cancer-related death, particularly lung cancer, which …
| 22 / 16 | Completed research grants |
| 32 / 11 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 56 / 29 | All research grants and scholarships |
| Associated processes | |